Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × eribulin × Lymphoid × Clear all

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 12 Lymphoid 1 Genitourinary 1

Conditions

Neoplasms 1 Lymphoma 1

Interventions

Rituximab 194 Cyclophosphamide 125 fludarabine 58 Vincristine 56 Methotrexate 56 Doxorubicin 47 Etoposide 44 Cytarabine 43 fludarabine phosphate 42 Prednisone 40 Lenalidomide 40 Filgrastim 39 Dexamethasone 39 Bortezomib 30 Whole-Body Irradiation 29 Radiotherapy 28 Gemcitabine 28 Mycophenolic Acid 26 Melphalan 26 Granulocyte Colony-Stimulating Factor 26 Bendamustine Hydrochloride 26 Calcium Dobesilate 25 Antilymphocyte Serum 25 obinutuzumab 24 Alemtuzumab 24 venetoclax 23 ibrutinib 23 Tacrolimus 22 Busulfan 22 Cyclosporine 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02082626 2020-03-10

ERIBULIN

University of Oklahoma

Phase 1 Terminated

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡